Arbutus Biopharma Corporation ABUS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborations and licenses | $204K-74.2% | $792K+183% | $280K-97.3% | $10.21M+676% | $1.32M+24.4% | |
| Non-cash royalty revenue | $181K-30.1% | $259K+4.0% | $249K-52.7% | $526K+17.4% | $448K-13.2% | |
| Revenue from collaborations and licenses | $178.74M— | $0-100% | $280K-97.1% | $9.62M+1,085% | $812K+39.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arbutus Biopharma Corporation break its business down?
- Arbutus Biopharma Corporation (ABUS) reports revenue by product across 3 parts — Collaborations and licenses, Non-cash royalty revenue and Revenue from collaborations and licenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Arbutus Biopharma Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arbutus Biopharma Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
